The FDA approved AbbVie’s Skyrizi to treat moderate to severe ulcerative colitis, adding another indication to the immunology drug’s arsenal.
AbbVie has said that UC …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1
New research at the Roy Blunt NextGen Precision Health building has discovered a potential treatment for an underlying cause of cardiovascular disease in people with
SynOx Therapeutics has completed a $75 million Series B raise to advance its monoclonal antibody drug through a registrational trial for a type of non-cancerous